STAT+: Pharmalittle: We’re reading about Sanofi and an FDA voucher, FDA rethinking a rejection, and more

Sanofi has asked the FDA to pull its type 1 diabetes drug from a speedy review program after a staff decision to approve the drug was disagreed with by the acting Center for Drug Evaluation and Research Director. An experimental drug from Revolution Medicines has shown promise in clinical trials for advanced pancreas cancer. The FDA is rethinking its approach to drug approvals.